All In Biotech

Free tool

FAERS Monitor: Beyaz

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022532 or its brand name (Beyaz, Drospirenone, Ethinyl Estradiol, Levomefolate Calcium). Reports on generic versions are filed under their own applications.

Reports

1,626

Serious

772

47% of reports

Hospitalization

456

Death reported

22

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pulmonary embolism310
  • deep vein thrombosis243
  • injury236
  • pain205
  • emotional distress163
  • anxiety148
  • drug dose omission97
  • no adverse event97
  • general physical health deterioration93
  • anhedonia84
  • metrorrhagia76
  • nausea69
  • dyspnoea63
  • thrombosis59
  • headache58

Reports by year received

View as table
YearReports
20102
2011332
2012457
2013360
2014164
201595
201683
201737
201824
201911
202018
202117
20225
20239
20244
20255
20263

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,533 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
metrorrhagiaSignal7657.946.54,178
deep vein thrombosisSignal24348.643.211,262
injurySignal23643.638.79,772
pulmonary embolismSignal31042.338.312,484
anhedoniaSignal8441.533.73,271
emotional distressSignal16317.415.12,520
general physical health deteriorationSignal9310.48.5785
thrombosisSignal599.57.4441
drug dose omissionSignal977.66.3553
no adverse eventSignal976.95.7490
anxietySignal1486.75.8726
painSignal2054.33.8535
dyspnoea631.41.18
headache581.20.92
nausea691.10.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.